Clovis (NASDAQ:CLVS) was forced to admit an unpleasant defeat after data emerged showing no significant difference in survival rates for advanced pancreatic cancer patients treated with the company's drug candidate CO-101 versus the current chemotherapy treatment, gemcitabine. The news caused the stock to drop by nearly 40% on Monday. In this video, Motley Fool health care analyst Brenton Flynn tells us how the company plans to move forward in the face of these big losses, and why this has been a difficult space for other companies as well.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.